Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Curis Inc (CRIS)

Curis Inc (CRIS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,630
  • Shares Outstanding, K 13,735
  • Annual Sales, $ 9,440 K
  • Annual Income, $ -7,580 K
  • EBIT $ -25 M
  • EBITDA $ -44 M
  • 60-Month Beta 3.02
  • Price/Sales 0.84
  • Price/Cash Flow N/A
  • Price/Book 1.37
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.92
  • Most Recent Earnings $-0.50 on 03/19/26
  • Next Earnings Date 05/05/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -1.25
  • Growth Rate Est. (year over year) +84.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5230 +6.21%
on 03/27/26
1.1300 -50.84%
on 03/02/26
-0.5845 (-51.27%)
since 02/27/26
3-Month
0.5230 +6.21%
on 03/27/26
1.2100 -54.09%
on 02/13/26
-0.5045 (-47.59%)
since 12/26/25
52-Week
0.5230 +6.21%
on 03/27/26
3.1300 -82.25%
on 06/11/25
-1.8545 (-76.95%)
since 03/27/25

Most Recent Stories

More News
Curis: Q4 Earnings Snapshot

Curis: Q4 Earnings Snapshot

CRIS : 0.5555 (-4.22%)
Curis Provides Fourth Quarter 2025 Business Update

Management to host conference call today at 4:30 p.m. ET

CRIS : 0.5555 (-4.22%)
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026

LEXINGTON, Mass. , March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 0.5555 (-4.22%)
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP

CRIS : 0.5555 (-4.22%)
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

LEXINGTON, Mass. , Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 0.5555 (-4.22%)
Curis Provides Updated Data from its Frontline AML Triplet Study

5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD)

CRIS : 0.5555 (-4.22%)
Curis to Present at Upcoming 30th Annual SNO Meeting

LEXINGTON, Mass. , Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 0.5555 (-4.22%)
Curis: Q3 Earnings Snapshot

Curis: Q3 Earnings Snapshot

CRIS : 0.5555 (-4.22%)
Curis Provides Third Quarter 2025 Business Update

Management to host conference call and webcast today at 4:30 p.m. ET

CRIS : 0.5555 (-4.22%)
Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

LEXINGTON, Mass. , Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...

CRIS : 0.5555 (-4.22%)

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

3rd Resistance Point 0.7230
2nd Resistance Point 0.6765
1st Resistance Point 0.6160
Last Price 0.5555
1st Support Level 0.5090
2nd Support Level 0.4625
3rd Support Level 0.4020

See More

52-Week High 3.1300
Fibonacci 61.8% 2.1341
Fibonacci 50% 1.8265
Fibonacci 38.2% 1.5189
Last Price 0.5555
52-Week Low 0.5230

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.